As­traZeneca looks to widen its lead over SGLT2 ri­vals with an­oth­er round of land­mark da­ta

Com­pe­ti­tion be­tween SGLT2 in­hibitors in the chron­ic kid­ney dis­ease field just got more in­ter­est­ing. This week­end, As­traZeneca went to the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy’s 2020 meet­ing armed with full da­ta from a Phase III tri­al of its Farx­i­ga for a new in­di­ca­tion in CKD.

The drug is up against Eli Lil­ly and Boehringer In­gel­heim’s Jar­diance, which re­ceived FDA fast-track des­ig­na­tion in March for a CKD in­di­ca­tion, and John­son & John­son’s In­vokana, which won ap­proval last Sep­tem­ber.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters